Lantern Pharma Inc. SEC Filings

Lantern Pharma is an A.I.-driven oncology company with three clinical-stage small-molecule candidates (LP-300, LP-184/STAR-001, LP-284) and an ADC program, built around its RADR^® and withZeta/Open-Medicine AI platforms. For the quarter ended June 30, 2026, it reported a net loss of $7.1 million versus $4.3 million a year earlier; the six‑month net loss was $10.4 million versus $8.9 million. Operating expenses fell as research and development dropped to $3.5 million for the first half of 2026 from $6.3 million, while general and administrative expenses rose modestly to $3.4 million.

Cash and cash equivalents were $6.7 million and marketable securities $0.7 million, with total assets of $8.6 million and a stockholders’ deficit of $3.2 million, driven largely by a new $7.5 million warrant liability. A May 2026 registered direct offering and concurrent private placement generated about $4.4 million of gross proceeds but also produced a non‑cash loss on warrant issuance and ongoing fair value remeasurement charges. Management discloses substantial doubt about the company’s ability to continue as a going concern without significant additional funding and plans to seek further capital, including via its ATM facility, collaborations, and grants, while continuing to progress its oncology and AI initiatives.

Empery Asset Management LP and Ryan M. Lane report beneficial ownership of Lantern Pharma Inc. common stock on a Schedule 13G. They report beneficial ownership of 1,322,551 shares of common stock, including 479,882 shares issuable upon exercise of warrants, representing 9.99% of the class. The percentage is based on 12,758,872 shares outstanding as of May 31, 2026, as reported by Lantern Pharma in a Form S-1. The warrants are subject to a 9.99% beneficial ownership limitation (the "Blocker"), so the reporting persons cannot exercise the warrants to the extent such exercise would cause them to beneficially own more than 9.99% of the outstanding common stock. All reported shares are held by funds managed by Empery Asset Management, and the reporting persons state that they may be deemed beneficial owners through their roles but each disclaims beneficial ownership of shares owned by another reporting person.

Lantern Pharma Inc. announced the formal creation of Open-Medicine AI (OMAI) as a separate company to commercialize and expand its multi-agent AI co-scientist platform, previously launched as withZeta.ai. OMAI and Lantern have executed commercial licensing agreements, approved by Lantern’s Board and consistent with the framework outlined in Lantern’s May 2026 registered direct financing. These agreements grant OMAI access to Lantern’s withZeta.ai-related models, data, algorithms, and other assets and personnel, positioning OMAI for independent growth while preserving strategic alignment with Lantern’s clinical programs and shareholders.

OMAI will advance a multi-agentic architecture first proven in oncology and rare cancer research and extend it into broader disease areas. Lantern has established Centers of Excellence in Dallas, Texas and Bengaluru, India, with the Bengaluru AI Center of Excellence created in the first quarter of 2026 to support development, refinement, and scaling of the Open-Medicine platform. Lantern cites projections that the global AI drug discovery and development market could exceed $10 billion by 2030, with oncology as the largest segment and compound annual growth rates above 30 percent. The platform includes coordinated specialist agents, multiple research modes, proprietary rare-cancer knowledge bases, and tools such as ZetaOmics™ for multi-omic analysis and generative chemistry capabilities, and is intended to pursue a dedicated funding and valuation path distinct from Lantern’s clinical activities.

Lantern Pharma Inc. has a significant shareholder, Thomas A. Satterfield, Jr., who reports beneficial ownership of 975,000 shares of common stock, representing 7.6% of the outstanding shares. This ownership includes both sole and shared voting and dispositive power over the shares.

Satterfield reports 95,000 shares over which he has sole voting and dispositive power and 880,000 shares over which he shares voting and dispositive power. The shared holdings are spread among jointly held shares with his spouse and several entities he controls or helps manage, including Tomsat Investment & Trading Co., Inc., Caldwell Mill Opportunity Fund, LLC, and A.G. Family L.P., as well as a limited power of attorney over additional shares held by his spouse.

Lantern Pharma Inc. has filed an S-1 to register up to 2,242,719 shares of common stock for resale by existing holders of warrants issued in a May 2026 financing. The company is not selling any new shares and will not receive proceeds from these resales.

Lantern may receive up to approximately $5.1 million if all registered warrants are exercised for cash at prices of $2.27 and $2.575 per share. As of March 31 2026 it held about $6.3 million in cash, cash equivalents and marketable securities and expects this to fund operations only until around the middle of the first quarter of 2027.

The company develops oncology drugs using its RADR A.I. platform and reports three clinical-stage small molecule candidates plus an ADC program. Its filings note recurring losses, negative operating cash flows and auditors’ substantial doubt about its ability to continue as a going concern without significant additional funding, alongside potential dilution and stock price volatility risks.

Lantern Pharma Inc. furnished an investor-style presentation used on June 1, 2026 to support discussions about the Harmonic™ Phase 2 clinical trial for its LP-300 product candidate. The presentation is attached as Exhibit 99.1 and is incorporated by reference for informational purposes.

The company notes that the material provided under this disclosure is considered "furnished," not "filed," which means it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.

Lantern Pharma Inc. (LTRN) received an updated ownership report from a group of Bios-related investment entities and principals via Amendment No. 7 to their Schedule 13D. The group reports beneficial ownership of 571,305 shares of Lantern Pharma common stock, representing 4.48% of the outstanding shares.

These shares are held across several funds, including Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT, with entities such as Bios Advisors GP, Bios Capital Management, Bios Equity Partners and Bios Equity Partners II, and individuals Aaron G.L. Fletcher and Leslie W. Kreis deemed to share voting and dispositive power.

The percentages are calculated using 12,758,872 Lantern Pharma shares outstanding, based on 11,304,697 shares from a Form 10-K and 1,454,175 additional shares from a Form 8-K. The filing states that, aside from any exceptions described, only the reporting persons have rights to dividends or sale proceeds for the reported shares.

Lantern Pharma reported first quarter 2026 results showing tighter cost control while advancing its oncology and AI platforms. Research and development expenses fell to approximately $1.7 million, a 47% year-over-year reduction, and net loss narrowed to about $3.3 million, down 27%, or $0.30 per share.

Cash, cash equivalents, and marketable securities were about $6.3 million as of March 31, 2026, and a registered direct offering on May 14, 2026 added roughly $4.4 million in gross proceeds, which the company believes will fund operations into the middle of the first quarter of 2027.

Operationally, Lantern advanced its LP-300 HARMONIC trial with a successful FDA Type C meeting, obtained FDA IND clearance for Starlight Therapeutics’ pediatric CNS cancer trial, launched its multi-agentic AI co-scientist platform withZeta.ai commercially, expanded the predictBBB.ai platform, and outlined plans to separate withZeta.ai into an independent AI-focused entity.